Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $4420.0000 (-1.78%) ($4350.0000 - $4535.0000) on Fri. Feb. 5, 2016. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 4.16% (three month average) | | RSI | 40 | | Latest Price | $4420.0000(-1.78%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | TNXP declines -1.8% a day on average for past five trading days. | | Weekly Trend | TNXP declines -3.5% a week on average for past two weeks. | | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability)
XLRE(17%) IBB(14%) XBI(14%) ARKG(13%) IWO(13%) | | Factors Impacting TNXP price | TNXP will decline at least -2.08% in a week (0% probabilities).
VIXM(-6%) TLT(-5%) GLD(-5%) BWX(-5%) SLV(-3%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -2.08% (StdDev 4.16%) | | Hourly BBV | 0 () | | Intraday Trend | -0.9% | | | | | |
|
| Resistance Level | $5032.75 | | 5 Day Moving Average | $4598(-3.87%) | | 10 Day Moving Average | $4771.19(-7.36%) | | 20 Day Moving Average | $5032.75(-12.18%) | | To recent high | -43.3% | | To recent low | 0% | | Market Cap | $1171.3b | | | | | | |
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |